Südzucker AG

  • WKN: 729700
  • ISIN: DE0007297004
  • Land: Deutschland

Nachricht vom 16.06.2021 | 17:32

Südzucker according to preliminary figures first quarter significantly below previous year - full-year forecast 2021/22 confirmed

Südzucker AG / Key word(s): Quarter Results
Südzucker according to preliminary figures first quarter significantly below previous year - full-year forecast 2021/22 confirmed

16-Jun-2021 / 17:32 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

In the first quarter of current fiscal year 2021/22 (1 March to 31 May 2021), Südzucker AG according to preliminary figures reached consolidated group revenues of about EUR 1.75 (previous year: 1.67) billion. The consolidated group operating result significantly decreased to about EUR 49 (previous year: 61) million.

Pandemic driven heterogeneous business development since first quarter 2020/21 led to numerous distortions within the quarters and within the whole business year 2020/21. They can lead partially to adverse effects within the quarters of current business year 2021/22. Against this background and the unchanged expectation of a further progress fighting the pandemic, Südzucker confirms its first group forecast dated 20 May 2021. We expect for fiscal year 2021/22 consolidated group revenues between EUR 7.0 and 7.2 (previous year: 6.7) billion. Consolidated group operating result is still expected to come in between EUR 300 and 400 (previous year: 236) million. Despite expected decreasing effects from the corona pandemic, there are still risks linked to the pandemic in business year 2021/22. The respective economic and financial impact and duration is still difficult to assess.

The full report for the first quarter 2021/22 will be published on 8 July 2021.

Südzucker AG
Maximilianstraße 10
68165 Mannheim, Germany

Investor Relations:
Nikolai Baltruschat

Phone: +49 621 421-240

16-Jun-2021 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de

show this

GBC im Fokus

IGEA Pharma N.V. Realignment to CBD extraction

The goal is to become the quality and cost leader in the field of CBD in Europe. To this end, a GMP pharma compliant plant is being built in Switzerland. The supercritical CO2 extraction process is to be used to achieve the highest standard of quality. The CBD market is growing strongly and with the focus on quality leadership and pure extraction, IGEA Pharma's new business model should be able to occupy an attractive niche market. With the proprietary supercritical CO2-extraction technology, other markets such as vanilla, rose or rosemary can be developed in the medium term. Based on our DCF model, we have determined a fair value of € 1.05 (CHF 1.13) per share and assign a BUY rating.

News im Fokus

Allianz SE: Allianz kündigt Abschluss eines Rückversicherungsvertrages in den USA an

03. Dezember 2021, 07:03

Aktueller Webcast

Deutsche Konsum REIT-AG

FY 2020/2021 Financial Results

16. Dezember 2021

Aktuelle Research-Studie

CEWE Stiftung & Co. KGaA

Original-Research: CEWE Stiftung & Co. KGaA (von GSC Research GmbH): Kaufen

02. Dezember 2021